Overview
On 20 March 2007, orphan designation (EU/3/07/437) was granted by the European Commission to Santhera Pharmaceuticals (Deutschland) GmbH, Germany, for idebenone for the treatment of Duchenne muscular dystrophy.
The name of the sponsor changed to Santhera Pharmaceuticals (Deutschland) GmbH in September 2010.
Key facts
Active substance |
idebenone
|
Intended use |
Treatment of Duchenne muscular dystrophy
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/07/437
|
Date of designation |
20/03/2007
|
Sponsor |
Santhera Pharmaceuticals (Deutschland) GmbH |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: